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Abstract
The background induced by the high penetration power of the γ ra-
diation is the main limiting factor of the current Radio-guided surgery
(RGS). To partially mitigate it, a RGS with β+-emitting radio-tracers
has been suggested in literature. Here we propose the use of β−-emitting
radio-tracers and β− probes and discuss the advantage of this method
with respect to the previously explored ones: the electron low penetration
power allows for simple and versatile probes and could extend RGS to tu-
mours for which background originating from nearby healthy tissue makes
γ probes less effective. We developed a β− probe prototype and studied
its performances on phantoms. By means of a detailed simulation we have
also extrapolated the results to estimate the performances in a realistic
case of meningioma, pathology which is going to be our first in-vivo test
case. A good sensitivity to residuals down to 0.1 ml can be reached within
1 s with an administered activity smaller than those for PET-scans thus
making the radiation exposure to medical personnel negligible.
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The radio-guided surgery (RGS) is a surgical technique, first developed some
60 years ago, that enables the surgeon to evaluate the completeness of the
tumoural lesion resection, while minimizing the amount of healthy tissue re-
moved [1]. The impact of the RGS on the surgical management of cancer
patients includes providing the surgeon with vital and real-time information
regarding the location and the extent of the lesion, as well as assessing surgi-
cal resection margins. The technique (see Fig. 1) makes use of a radio-labelled
tracer, preferentially taken up by the tumour to mark the cancerous tissue from
the healthy organs, and a probe (for a review see [2]), sensitive to the emission
released by the tracer, to identify in real time the targeted tumour loci. The
radio-pharmaceutical is administered to the patient just before the surgery.
Current clinical applications of the RGS are: radio-immuno-guided surgery
(RIGS) for colon cancer, complete sentinel-node mapping for malignant melanoma
and breast cancer, and detection of parathyroid adenoma and bone tumours
(such as osteoid osteoma).
Established methods make use of a combination of a γ-emitting tracer with
a γ radiation detection probe (see [3] and references therein). Since γ radiation
can traverse large amounts of tissue, any uptake of the tracer in nearby healthy
tissue represents a non-negligible background, often preventing the usage of this
technique.
To mitigate this effect it was suggested in literature the use of β+ decaying
tracers [4]. The emitted positrons in fact have a limited penetration and their
detection is local. Nonetheless, positrons annihilate with electrons in the body
and produce γs with an energy of 511 keV: the background persists and actually
increases in energy. The improvement with respect to the use of pure γ emitters
is that a dual system can be devised where the background can be measured
separately and subtracted from the observed signal. This approach has been
studied in preclinical tests [5] but it is not yet in use in the clinical practice.
The largest limitations range from the time needed to identify a residual, the
dimensions of the probes and the dose absorbed by the medical personnel.
A better solution to the current limits of RGS would be to eliminate the
background from γ radiation. This study suggests therefore the use of pure
β− radiation that penetrates only a few millimetres of tissue with essentially
no γ contamination, being the bremsstrahlung contribution, with a 0.1% emis-
sion probability, negligible. Furthermore, a β− probe, detecting electrons and
operating with lower background, provides a clearer delineation of margins of
the radioactive tissue, requires administration of a radio-pharmaceutical with a
lower activity and it is smaller and easier to handle in the surgical environment.
The lower absorbed dose, together with the short range of electrons, implies an
almost negligible radiation exposure to medical personnel and therefore a larger
number of RGSs per year for the surgeon.
The idea of detecting β− emission was first proposed at the very beginning
of the development of RGS [6]. However, it was soon abandoned due to the par-
ticular phenomenology of this emission. The short electron free-path demanded
for low invasiveness detectors to be used intra-operatively in contact with the
tissues and sensitive enough to absorbed dose normally accepted in nuclear
medicine. Both requirements were not satisfied by instruments and materials
available at the time, while are easily reachable with modern technologies.
In particular, we report on the developments in the field of the radio-tracers
and in the development and test of a specific intra-operative probe device that
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make the RGS with β− decays feasible.
Results
The clinical case. There are several possible applications of this technique,
many of which probably have not yet been thought of. First, complete removal
of tumour is critical for brain tumours, where a relapse is particularly dangerous
and where other RGS techniques are limited by the high uptake of the brain.
Next, particular attention should be paid to the complete resection of the main
tumour and of infected lymph-nodes in the case of pediatric tumours where life
expectancy is long. Such tumours are typically abdominal and therefore probe
signals are blinded by background from kidneys, liver and bladder. Finally,
there are abdominal tumours in adults, like non-palpable metastases in liver
and insulinoma, that would profit from RGS.
Testing this novel technique with most of the above-mentioned clinical cases
requires first to identify and test an appropriate β−-emitting tracer. We then
focused on a brain tumor for which such a tracer already exists. Based on our
experience with the Peptide Receptor Radionuclide Therapy (PRRT) [7, 8, 9],
the meningioma has been chosen: this brain tumor is particularly receptive
to synthetic somatostatin analogues, such as DOTATOC, that can be labelled
with the β− emitting 90Y. Furthermore, the same tracer can be marked with
68Ga, thus allowing for an estimate of uptake prior to surgery with a Positron
Emission Tomography (PET) exam. Finally, it was recently shown that with
an appropriate SPECT device also the brehmsstrahlung emission of the 90Y can
be use to verify the receptivity [10].
The β− detecting probe. As far as the probe design is concerned, the choice
of the materials and the readout electronics is driven by the need to maximize
the sensitivity to electrons while minimizing the sensitivity to photons. Para-
terphenyl, or p-terphenyl, was adopted as electron detector after a detailed
study [11] due to its high light yield and low density, with consequent low
sensitivity to photons.
A first prototype of the β− probe was developed (see Fig 2) and tested with
phantoms using 90Y diluted in a physiological saline solution (see Methods for
the experimental set-up and Supplementary Information for more details on
the test results). We explored the range of activity concentration from 22 to
5 kBq/ml to be compared with the 20 kBq/ml value estimated by analyzing
PET DICOM images obtained administering 3 MBq/kg of 68Ga-DOTATOC to
patients affected by meningioma. We therefore studied the probe performance
close and below the activity range achieved for diagnostic investigation.
We explored the first prototype response with four phantoms simulating
cancerous residuals with different topologies (see Supplementary Fig. S1). The
0.1 ml volume phantom, referred to as ”RESIDUAL”, has dimensions compati-
ble with residuals well identified with the nuclear magnetic resonance. To check
the effect of the phantom depth on the probe response and resolution in distin-
guishing the residual edge, the other three cylindrical phantoms have the same
activity concentration, footprint (13 mm2) but different heights: 1, 2, and 3 mm
referred to as ”H1”, ”H2, ”H3” respectively.
A 1.5 mm step blind automated scan over the phantom engraved surface
was performed when the activity concentration reached 16 kBq/ml. Even by
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limiting the acquisition time to 1 s per step the test demonstrated that all the
residuals would be identifiable in absence of background from nearby organs.
The signal from the tumor residuals was studied at maximum and minimum
activity concentrations, 22 and 5 kBq/ml, and the observed rates are reported
in Tab. 1. The electronic noise was found to be negligible. Background rates,
dominated by the signal coming from the uptake of nearby healthy tissue, were
estimated using a full simulation of the system with FLUKA program [12], based
on the above mentioned DICOM images showing that the nearby healthy tissue
uptake is approximately 10 times smaller than the tumour.
From the signal and background rates, taking into account the Poisson fluc-
tuations of the measured counts, we computed the false-positive (FP) and the
false-negative (FN) rates for a given time interval measurement with the probe.
We estimated (see Tab. 1) the time needed to achieve FP≈ 1% and FN< 5%
and found it to be 1 s for 22 kBq/ml activity concentration and up to 10 s in the
case of a concentration as low as 5 kBq/ml. Further improvements of the probe
are needed to reduce such time at a level compatible with surgical environment
and administer down to 5 kBq/ml.
The effect of an off-axis measurement has been verified by moving the probe
away from the phantom centre. The test showed that the rate is reduced by
a factor 2 when moving the probe 0.5 mm far from the phantom edge (see
Supplementary Fig. S4). This allows us to conclude that the probe distinguishes
the residual edge. This test also demonstrated the lateral shielding effectiveness
of this prototype making the probe insensitive to electrons coming from the sides
hence increasing the tumor-spotting capability. This test also shows that the
probe is insensitive of long-range radiation that could be caused by the activity
of the 90Y in nearby samples.
Radiation exposure to patient and medical personnel One of the key
points of this technique is the low irradiation of the patient and above all of the
medical staff. As previously mentioned, we estimated that a 22 kBq/ml activity
concentration, corresponding to administering approximately 3 MBq/kg, would
be more than sufficient for the technique to be effective.
From Ref. [9] we obtained that the total body dose absorbed by a 70 kg
patient after administration of 210 MBq of 90Y-DOTATOC is approximately
21 mSv, while the effective dose is about 70 mSv. This corresponds to approxi-
mately two Computed Tomography (CT) exams and therefore there is room for
improvement in reducing the required activity.
To evaluate the dose absorbed by the surgeons we simulated a set-up similar
to the common situation of an operating room. Both activities of neoplastic
cells and normal tissue were taken into account, according to the ratios ob-
tained from the aforementioned studies on PET images. The equivalent dose
absorbed by the surgeon’s hands computed for RGS with a 90Y emitting tracer
is expected to be smaller than 1 µSv/hour. The corresponding value for estab-
lished RGS with 99mTc radio-label tracer is 24 µSv/hour as estimated with the
simulation, which was consistent with Ref. [1]. Similarly, the total-body dose to
the surgeon is 0.13 µSv/hour with the β− RGS here proposed, to be compared
with approximately 6 µSv/hour of the 99mTc RGS.
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Discussion
The radio-guided surgery represents a very useful surgical adjunct in those cases
where a complete resection, intended as full enhancing mass removal, is crucial
both for recurrence-free survival and the overall survival of the patients, partic-
ularly for those tumours where the surgical mass removal is the only possible
therapy.
We are proposing a radical change in the paradigm of this technique: the use
of β− radiation instead of γ or β+ radiation. The reduced penetration power
of electrons should allow the extension of this technique to clinical cases that
would be otherwise prevented by the presence of nearby healthy organs taking
up the tracer.
This novel approach allows to develop a simple and compact probe which,
detecting electrons and operating with low radiation background, provides a
clearer delineation of margins of radioactive tissue and requires a smaller radio-
pharmaceutical activity to detect tumour remnants compared to traditional
RGS approaches. Moreover, due to the lower absorbed dose and the short
range of electrons, the radiation exposure to the patient and medical personnel
becomes almost negligible. Such considerations apply also in the comparison
with the β+ RGS, since in the latter the γ background is in any case present,
albeit subtracted with the dual-probe approach. Furthermore, measurements
performed in absence of background, as in the case of the proposed β− RGS, re-
quire by definition shorter read-out times than measurements with background
subtraction. Finally, the need to duplicate the probe for the background esti-
mation makes β+ probes intrinsically less compact.
We have presented pre-clinical tests of a prototype probe supporting the
above statements. From these measurements we extrapolated with a detailed
simulation the expected performance with meningioma, representing our test
clinical case. Nonetheless, the actual uptake on the margins of the lesion, the
impact of tissue between the probe and the residual and the effect of the nearby
blood is something to be estimated in clinical tests. Once the feasibility of such
technique will be demonstrated with meningioma, it will be possible to extend
it to other clinically relevant cases, eventually together with the development of
specific radio-tracers.
Methods
The probe prototype. The core of the probe (see Fig. 2) is a cylindrical
scintillator (diameter 2.1 mm, height 1.7 mm) of poli-crystalline para-terphenyl
doped by 0.1% in mass of diphenylbutadiene. Para-terphenyl was adopted, after
a detailed study [11], due to its high light yield (3.5 times larger than typical
organic scintillators), non-hygroscopic property and low density. The scintilla-
tor is shielding against radiation coming from the sides by wrapping it with a
7 mm external diameter ring of PVC. The device is encapsulated inside an easy-
to-handle aluminum body, as protection against mechanical stress, and has a
blinding 0.4 mm-thick black PVC front end cap. The scintillation light is trans-
ported to a photo-multiplier tube (PMT, Hamamatsu H10721-210), through an
optical fibre, and read out by a portable custom electronics with wireless con-
nection to a PC or tablet. This prototype is compatible with a standard sterile
covering of sub-millimetric film for surgical environment. Also the very low bias
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required by the PMT, 5V, makes the device easily portable.
Experimental set-up of the 90Y test. The phantoms are cylindrical vessels,
engraved at a fixed radius on a PMMA (PlexiglassTM) disk mounted on a rotating
table, as shown in supplementary Fig. S1. Their dimensions are listed in Tab. 1
and are known with a precision of 10 µm.
During the test, the probe was fixed in vertical position over the disk and
the phantoms were moved under the probe by rotating the disk with a step
motor, controlled via PC. The relative position of the sensitive head of the
probe and the phantom was known with a precision of 10 µm. Two probe-disk
distances were studied: 50 and 150 µm. At the optimal working point (PMT
gain ∼106 and signal readout threshold of 21 mV), the background rate due
to the photo-multiplier tube dark current and casual events was measured to
be 0.2 counts per second (cps). It was checked to be stable when operating at
room-temperature and with ambient light conditions.
Estimate of false positive and false negative rates. The rate of false
positive and false negative (FP and FN) is computed from the signal (νs) and
background (νb, mostly due to tracer uptake in healthy tissue) rates estimated,
for each phantom, as described in the Results section. For a given value of the
probe acquisition time (tdaq), the number of signal counts from the tumour and
the background is distributed according to a poisson distribution with mean
µs = νstdaq and µb = νbtdaq, respectively. Given the minimum number of signal
counts needed to flag a positive identification th, FP is computed as the fraction
of times the background would yield a positive signal:
FP = 1−
th−1∑
N=0
Pµb(N) (1)
where Pµ(N) indicates the Poisson probability to have N if the mean is µ.
Similarly FN is the fraction of times a tumour residual would not yield a signal
FN =
th−1∑
N=0
Pµs(N). (2)
To determine the minimum acquisition time reported in Tab. 1, FN and
FP are computed in a grid of tdaq and th (see Supplementary Fig.S5) and the
smallest value of tdaq for which FN< 5% and FP≈ 1% is determined.
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Phantom Diameter Height Volume Rate (cps) T (s) Rate (cps) T (s)
(mm) (mm) (ml) 22 kBq/ml 22 kBq/ml 5 kBq/ml 5 kBq/ml
Residual 6 3.5 0.10 31.6 1 6.6 2
H1 4 1 0.01 12.4 2 2.6 >10
H2 4 2 0.02 17.7 1 3.7 4
H3 4 3 0.04 20.1 1 4.2 4
Table 1: Results of the test on the first probe prototype. The probe was
tested on phantoms sized as possible tumour residuals of interest, filled with 90Y
in saline solution to simulate the situation after bulk meningioma removal. The
rates measured with two different 90Y activity concentrations (22 and 5 kBq/ml)
are reported (Rate). The minimal acquisition time (T) needed to detect tumour
residuals with a false-negative probability <5% and a false-positive probability
∼1% was estimated extrapolating the laboratory test results to a real case by
means of a detailed simulation.
Supplementary Information
Probe test in laboratory
Supplementary Discussion on the probe test results. We observed that
the probe prototype is able to detect samples of millimetric dimensions and
different topologies in the whole activity concentration range suitable for diag-
nostic investigation (5-22 kBq/ml). The counts-per-second (cps) measured by
the probe on any phantom decrease, as expected, with the 90Y activity accord-
ing to the radionuclide decay law, as shown in Supplementary Fig. 4 for the
RESIDUAL phantom.
To test the detection efficiency of the probe and its sensitivity to different
phantom topologies, we performed a blind scan simulating the surgeon exploring
the area to look for residuals. Fixing the probe position over the phantom disk
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Figure 1: The radioguided surgery technique (RGS). Steps of the pro-
cedure: (1) a radio-labelled tracer is administered to the patient, before the
surgery; (2) the emitting tracer is preferentially taken up by the tumour; (3) af-
ter the cancerous bulk removal, the surgeon explores the lesion with a radiation
detecting probe and looks for targeted tumour residuals in real time.
The bottom boxes show the effect of the proposed replacement of the γ-emitting
tracers (a) with electron-emitting tracers (b). Due to the high penetration power
of the photons, in the first case a non-negligible background can be produced by
the healthy organs close to the lesion, sometimes preventing the applicability of
the technique. To mitigate this effect a shielding or active veto is applied (see
inset of box a) thus making the probes cumbersome. Electrons, instead, provide
a clearer delineation of radioactive tissue’s margins allowing for a simple and
compact probe and requiring a smaller radio-pharmaceutical activity.
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Figure 2: First prototype of the intraoperative β− probe. The core is a
cylindrical scintillator (diameter 2.1 mm, height 1.7 mm) of poli-crystalline p-
terphenyl. A ring of PVC wraps the scintillator and shields it against radiation
coming from the sides. The device is encapsulated inside an easy-to-handle alu-
minum body as protection against mechanical stress and it is protected against
light by a thin PVC layer.
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Figure 3: Experimental set-up. The probe and the automated disk with
phantoms for the 90Y tests.
with a random offset with respect to the phantom positions, we rotate the
motorized table by a complete turn with 1 degree step angle (corresponding to
1.5 mm step along the circumference) recording a 1 s-long rate measurement at
each step. As shown in Supplementary Fig. 5 all four phantoms were clearly
detected at the 16 kBq/ml 90Y activity concentration. Furthermore, the absence
of a signal when the probe was located in between the samples demonstrates the
insensitivity to any long-range radiation that could be produced by the activity
of the phantoms.
The effect on the probe sensitivity of different phantom’s footprints and of
the radioactive volume thickness was also tested. As shown in Supplementary
Fig. 6, moving the probe away from the phantoms results in a decrease in rate,
which is halved when the centre of the probe is 0.5 mm from the edge of the
sample. This is true for any phantom shape demonstrating that the depth of
the sample does not affect the sensitivity of the device to the phantom’s edge,
making it possible to identify the real dimension of the active area.
In conclusion we verified that by administering a 90Y activity similar to those
used for diagnostic purposes, the probe prototype is able to identify millimetric
radioactive volumes. It can detect the real dimension of the phantoms providing
10
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Figure 4: Counts-per-second observed during 1 week by the probe over
the RESIDUAL phantom filled with 90Y in physiological saline solu-
tion. As expected, the rate decreases as the 90Y activity. The superimposed
line is the result of a fit with lifetime fixed to the one of 90Y.
a fast response.
Determination of the minimal acquisition time.
Supplementary Fig. 7 shows the combination of th and tdaq with FP≈1% and
FN< 5%. These curves were used, as described in the Methods section, to
estimate the minimum acquisition time needed at each activity.
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Figure 7: Determination of the minimal acquisition time. As described in
the Methods section, FN and FP depend on the acquisition time (tdaq) and the
minimum signal required to claim a positive evidence (th). By requiring a false-
positive probability of ∼1% and a false-negative probability <5% the allowed
working points for tdaq and th are described. The results for the four phantoms
under study are compared considering administration of radio-pharmaceutical
with three different activity values. These curves were estimated in the first test
medical case, the meningioma marked with 90Y-DOTATOC.
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